ArticleFrontiers in medicine2025
Validation of "Clinical Red Flags" for RA-ILD in an Italian cohort.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the Diagnosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Integrating Conventional Tools and Emerging Biomarkers.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rheumatoid arthritis (RA) is a systemic inflammatory disease, characterized by articular and extra-articular manifestations, including Interstitial Lung Disease (ILD). An early diagnosis of ILD can be essential in improving disease outcome. A clinical practice checklist has previously been proposed, highlighting red flags in signs and symptoms suggestive of RA-ILD. Our aim was to validate the "checklists of red flags signs or symptoms suggestive of RA-ILD" in our cohort of RA patients, by assessing the diagnostic utility of dyspnea, cough, and crackles, both individually and in combination. Methods: We performed a retrospective study including medical charts of consecutive RA patients fulfilling 2010 ACR/EULAR classification criteria. The diagnosis of RA-ILD was based on the chest HRCT exam. The primary symptoms and signs of ILD, namely cough, crackles, and dyspnea, were considered separately and in combination to determine diagnostic performance metrics. Results: Our cohort included 107 patients with RA, from which 55 (51.4%) with a diagnosis of RA-ILD. Female patients were predominant in both RA-ILD and No-ILD groups (56.4 and 82.6% respectively), with a significantly higher proportion in the latter ( Conclusion: Overall, crackles and dyspnea were the most significant markers of RA-ILD, both individually, and in combination. This study confirms that the red flags previously identified, especially in combination, show an important accuracy and reliability as clinical biomarkers in the early detection of RA-ILD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.